RHOBTB1: A BTI for Cancer Treatment (G9886)

Target Name: RHOBTB1

NCBI ID: G9886

RHOBTB1

RHOBTB1: A BTI for Cancer Treatment

The Basal Translocation Inhibitor (BTI) class of drugs is a new class of therapeutics that are being developed for the treatment of various diseases, including cancer. These drugs work by inhibiting the process of basal translocation, which is the movement of proteins from one chromosome to another. This process is critical for the development and maintenance of cancer cells, and therefore, inhibiting it can be an effective way to treat cancer. One of the BTIs that is currently being developed is RHOBTB1 (Rho-related BTB domain containing 1) , which is a drug target (or biomarker) that may be useful for the treatment of various diseases.

The discovery of RHOBTB1

RHOBTB1 was first identified as a gene that was expressed in various tissues and organs, including the brain, spleen, and pancreas. The gene is located on chromosome 1 and has a length of 241 amino acids. RHOBTB1 is a member of the BTI family and is characterized by the presence of a Rho-related BTB domain. This domain is a unique feature that is found in a number of BTIs, and it is thought to play a critical role in the inhibition of basal translocation.

The biology of RHOBTB1

RHOBTB1 is a non-coding RNA molecule that is made up of 241 amino acids. It is located on chromosome 1 and has a unique structure that is specific to this gene. The Rho-related BTB domain is the most notable feature of RHOBTB1, and it is located at the beginning of the gene. This domain is composed of 22 amino acids and has a characteristic structure that is composed of a hydrophobic core and a hydrophilic tail. The core of the domain is made up of three beta-helices, and the tail is made up of a variety of amino acids, including alanine, glutamic acid, and aspartic acid.

The function of RHOBTB1

The function of RHOBTB1 is not well understood, but it is thought to play a critical role in the inhibition of basal translocation. Basal translocation is the movement of proteins from one chromosome to another, and it is a critical process for the development and maintenance of cancer cells. RHOBTB1 is thought to inhibit this process by interacting with the protein called p21, which is a transcription factor that is involved in the regulation of gene expression.

The structure of RHOBTB1

The structure of RHOBTB1 is highly conserved, and it is similar to the structure of other BTIs. It has a characteristic alpha-helical arrangement and a unique 3D structure that is specific to this gene. The Rho-related BTB domain is located at the beginning of the gene and is composed of three beta-helices. The first beta-helix is 鈥嬧?媗ocated at the N-terminus of the domain, and the second and third beta-helices are located in the middle and C-terminus of the domain, respectively.

The role of RHOBTB1 in cancer

RHOBTB1 is a potential drug target (or biomarker) for the treatment of various diseases, including cancer. The inhibition of basal translocation by RHOBTB1 is thought to be a key mechanism of its anti-cancer effects. By inhibiting the movement of proteins from one chromosome to another, RHOBTB1 may be able to prevent the formation of new cancer cells. Additionally, the Rho-related BTB domain of RHOBTB1 may be involved in the regulation of cell

Protein Name: Rho Related BTB Domain Containing 1

The "RHOBTB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RHOBTB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets